Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Research Site
 (8.7 away) Contact site
  • 147 views
  • 03 Jun, 2021
  • +262 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (8.7 away) Contact site
  • 211 views
  • 02 Jun, 2021
  • +361 other locations
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent …

transitional cell carcinoma
docetaxel
erdafitinib
advanced urothelial carcinoma
carcinoma
Friedrich-Alexander Universitaet Urologische Universitaetskl
 (8.7 away) Contact site
  • 271 views
  • 03 Jun, 2021
  • +587 other locations
Linerixibat Long-term Safety and Tolerability Study

This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior eligible clinical trial with linerixibat. Participants will be administered with 90 milligrams (mg) linerixibat orally twice daily. The …

cholestatic pruritus
cholangitis
GSK Investigational Site
 (8.7 away) Contact site
  • 0 views
  • 21 Mar, 2021
  • +21 other locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Research Site
 (8.7 away) Contact site
  • 50 views
  • 02 Jun, 2021
  • +222 other locations
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with moderate plaque psoriasis. Adverse events and change in disease symptoms will be monitored. …

apremilast
systemic therapy
plaque psoriasis
risankizumab
arthritis
Universitaetsklinikum Erlangen /ID# 229433
 (8.7 away) Contact site
  • 0 views
  • 19 Jun, 2021
  • +54 other locations
Dasatinib Holiday for Improved Tolerability

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment nave disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

bosutinib
dasatinib
imatinib
leukemia
potassium
Gemeinschaftspraxis Erlangen
 (9.5 away) Contact site
  • 11 views
  • 05 Feb, 2021
  • +79 other locations
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma

Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA. 200 patients will be included. The Trial is an open multicenter Phase III Trial.

metastasis
therapeutic autologous dendritic cells
University Hospital Department of Ophtalmology
 (8.7 away) Contact site
  • 16 views
  • 09 May, 2021
  • +11 other locations
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using …

Universitaetsklinikum Erlangen, Medizinisches Klinik 4, Ulmenweg 18
 (8.7 away) Contact site
  • 735 views
  • 26 Jan, 2021
  • +153 other locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group. The leukemia cells present themselves with quite differently activated regulatory mechanisms of the malignant phenotype. The introduction …

dexamethasone
methotrexate
acute leukemia
pegaspargase
fludarabine
Universitaets - Kinderklinik
 (8.7 away) Contact site
  • 562 views
  • 26 Jan, 2021
  • +167 other locations